AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Licensing agreement will focus on vaccine development.(Brief Article)
2002 AUG 7 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell N.V. (CRXL) and Genexine Co., Ltd., a Korean drug development company, announced that they have entered into a licensing agreement wherein Crucell's PER.C6 cell line will be used by Genexine for the research, development, and manufacture of a recombinant therapeutic vaccine against hepatitis B.
Under the terms of the agreement, Genexine obtains a worldwide nonexclusive license for the use of Crucell's PER.C6 cell line to research and develop a therapeutic vaccine against hepatitis B. Furthermore, the agreement includes the option for a commercial license. Crucell will receive upfront and annual payments; further financial details were not disclosed.
"400 million individuals world-wide are hepatitis B virus (HBV) carriers running the risk of developing cirrhosis and eventually liver cancer. It has recently been shown in an animal model that a vector-based vaccine may be able to reduce the HBV viremia. This makes ...
- Crucell Revenues EUR 2.0 Million in Third Quarter 2002.
- Press release article from: PR Newswire October 14, 2002 700+ words
...Third Quarter 2002 -- Crucell and Genexine announce PER.C6...Hepatitis B vaccine -- Crucell and the US National...with Korean company Genexine, an agreement with...same quarter in 2001. Crucell's revenues are related...
- A Co-Development Contract Between 'Dong-A Pharm' and 'Genexine' as Win-Win...
- Press release article from: PR Newswire June 13, 2007 700+ words
...leading Pharmaceutical company, and Genexine (CEO, Young Chul Sung), a drug development...of 2nd generation protein drugs using Genexine's propriotery hybrid Fc-fusion technology...development pipelines for new drugs. Genexine is hoping to launch products in the market...
- Co-development deal for Dong-A, Genexine.(Dong-A Pharmaceutical Company...
- Newspaper article from: Pharma Marketletter June 25, 2007 700+ words
...drugmaker, Dong-A Pharmaceutical, and Genexine, a development-stage biotechnology...of second generation agents utilizing Genexine's propriotery hybrid Fc-fusion technology...reinforce its development pipeline. Genexine is hoping to launch products as soon...
- Genexine Co., Ltd.-Company Report.
- Press release article from: M2 Presswire January 25, 2009 700+ words
...PRESSWIRE-25 January 2009-www.companiesandmarkets.com: Genexine Co., Ltd.-Company Report(C)1994-2009 M2 COMMUNICATIONS...25012009 -www.companiesandmarkets.com adds new report: Genexine Co., Ltd.-Company Report Private Company Reports provide...
- Crucell Appoints VP Development and Regulatory Affairs.
- Press release article from: PR Newswire January 17, 2002 700+ words
...Dutch antibody and vaccine company Crucell (Nasdaq, Euronext: CRXL) today announced...per March 1, 2002. Prior to joining Crucell, Dr. Heylen was VP Medical Affairs for...regulatory affairs and pharmacovigilance. At Crucell Dr. Heylen will handle all contacts with...
- Crucell and GeneMax enter PER.C6 license agreement in gene delivery field to...
- Press release article from: PR Newswire August 12, 2003 700+ words
...PRNewswire/ -- Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL) and...they have entered a license agreement for Crucell's PER.C6(TM) cell line technology...terms of the agreement, GeneMax will use Crucell's PER.C6(TM) technology for research...
- Crucell Spin-Out Galapagos Genomics NV to Complete a Private Placement.
- Press release article from: PR Newswire March 4, 2002 700+ words
...Dutch antibody and vaccine company Crucell N.V. (Nasdaq: CRXL; Euronext) today...of venture capital firms not related to Crucell. Financial details will be disclosed...Galapagos Genomics NV was founded by Crucell to exploit its proprietary human cell...
- Crucell Appoints VP Corporate Development & Strategy.
- Press release article from: PR Newswire August 29, 2001 700+ words
...Netherlands, Aug. 29 /PRNewswire/ -- Crucell N.V. (Nasdaq: CRXL) (Euronext Amsterdam...Amir-Aslani will be responsible for Crucell's investor relations and corporate marketing...European biotech companies. Prior to joining Crucell Dr. Amir-Aslani was heading the life...
Source: HighBeam Research, Licensing agreement will focus on vaccine development.(Brief Article)